Developer docs
API playgroundTry for free, no card

Search company profiles

OrphoMed

Full company profile

uuid0002p1w

Namestring
OrphoMed
Websiteurl
orphomed.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

OrphoMed is a privately held pharmaceutical company founded in 2015 and headquartered in Mill Valley in the San Francisco Bay Area. Per its short description, it is focused on the development of novel therapeutics, operating as a small organization of 1-10 employees consistent with a clinical- or preclinical-stage drug development start-up. The company is led by co-founders Frank Steinberg (Co-Founder & Medical Advisor) and Pankaj Pasricha, supported by a small senior team covering operations (Dennie Dyer, VP), regulatory and quality affairs (Sharon Sakai, VP), and chemistry (Rajeshwar Singh, Acting VP), reflecting a build-out typical of a development-stage pharma advancing a candidate toward IND-enabling work.

The company's capital structure to date consists of a $2.8M financing recorded in January 2016 followed by a $39M round in May 2017 co-led by New Enterprise Associates and Takeda Ventures, with participation from Mario Family Funds, Pappas Capital, and Relativity Healthcare Partners. The involvement of Takeda Ventures, a strategic corporate venture arm, alongside specialist biotech investors is consistent with a company building toward a partnership- or licensing-relevant asset. Specific therapeutic indications, lead compounds, mechanism of action, trial status, and intellectual property details are not disclosed in the available input.

OrphoMed's current commercial position is pre-revenue: there are no disclosed products, pricing, customers, or partnerships beyond the investor syndicate, and the corporate website (orphomed.com) currently resolves only to a verification/loading page with no substantive content. As a result, the business model is best characterized as venture-funded drug discovery and development, with future monetization likely dependent on out-licensing, partnership, or acquisition rather than direct commercialization given the company's scale.

Short descriptiontext

OrphoMed is a privately held, clinical-stage pharmaceutical company founded in 2015 in Mill Valley, California, developing novel therapeutics with a small team and venture funding from NEA, Takeda Ventures, and other biotech investors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMill Valley, United States
HQ citystring
Mill Valley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
novel therapeutics development, small molecule drugs, pharmaceutical research, clinical-stage biopharma, drug discovery
Industry1 code
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Pharmaceutical Drug Development
Social media profiles2 records
Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

OrphoMed is a San Francisco Bay Area pharmaceutical company founded in 2015 that develops novel therapeutics. The firm operates a small, focused R&D operation (1-10 employees) and has been funded by life-sciences venture investors to advance its pharmaceutical pipeline from medicinal chemistry through regulatory development.

Differentiator
Functional benefit
Problem solved
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers7 records
TypeBroad incumbent
Description

Large pharmaceutical strategic that led OrphoMed's Series A through Takeda Ventures, with a substantial GI specialty franchise (including the former Shire GI portfolio) making it both a potential acquirer and a directly relevant commercial comparator.

TypeDirect peer
Description

Clinical-stage specialty pharmaceutical company developing novel therapeutics for GI and cardiorenal disorders, closely comparable to OrphoMed's small-molecule, GI-focused drug development model.

TypeDirect peer
Description

GI-focused specialty pharmaceutical company developing therapeutics for IBS and other GI motility disorders, making it a directly comparable peer in target indication and therapeutic category.

4Synthetic Biologics
TypeEmerging player
Description

Small-cap clinical-stage pharmaceutical company developing GI-focused therapeutics, comparable to OrphoMed in stage, size, and therapeutic category overlap.

TypeDirect peer
Description

Specialty pharma focused on GI and infectious diseases with a small-molecule pipeline, comparable to OrphoMed in size, stage, and therapeutic focus on GI disorders.

TypeBroad incumbent
Description

Established commercial-stage GI specialty pharma and a potential strategic acquirer of OrphoMed's assets; offers directly competing and complementary therapies in IBS-D and related GI conditions.

TypeDirect peer
Description

Specialty pharma that developed therapies for IBS-D and chronic GI conditions, providing a directly comparable business model, indication focus, and small-cap pharma profile (despite later restructuring).

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OrphoMed

Pharmaceutical Drug Developmentorphomed.com

OrphoMed is a privately held, clinical-stage pharmaceutical company founded in 2015 in Mill Valley, California, developing novel therapeutics with a small team and venture funding from NEA, Takeda Ventures, and other biotech investors.

What OrphoMed does

OrphoMed is a privately held pharmaceutical company founded in 2015 and headquartered in Mill Valley in the San Francisco Bay Area. Per its short description, it is focused on the development of novel therapeutics, operating as a small organization of 1-10 employees consistent with a clinical- or preclinical-stage drug development start-up. The company is led by co-founders Frank Steinberg (Co-Founder & Medical Advisor) and Pankaj Pasricha, supported by a small senior team covering operations (Dennie Dyer, VP), regulatory and quality affairs (Sharon Sakai, VP), and chemistry (Rajeshwar Singh, Acting VP), reflecting a build-out typical of a development-stage pharma advancing a candidate toward IND-enabling work.

The company's capital structure to date consists of a $2.8M financing recorded in January 2016 followed by a $39M round in May 2017 co-led by New Enterprise Associates and Takeda Ventures, with participation from Mario Family Funds, Pappas Capital, and Relativity Healthcare Partners. The involvement of Takeda Ventures, a strategic corporate venture arm, alongside specialist biotech investors is consistent with a company building toward a partnership- or licensing-relevant asset. Specific therapeutic indications, lead compounds, mechanism of action, trial status, and intellectual property details are not disclosed in the available input.

OrphoMed's current commercial position is pre-revenue: there are no disclosed products, pricing, customers, or partnerships beyond the investor syndicate, and the corporate website (orphomed.com) currently resolves only to a verification/loading page with no substantive content. As a result, the business model is best characterized as venture-funded drug discovery and development, with future monetization likely dependent on out-licensing, partnership, or acquisition rather than direct commercialization given the company's scale.

OrphoMed firmographics

Firmographics
Name
OrphoMed
Website
https://orphomed.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
OrphoMed is a privately held, clinical-stage pharmaceutical company founded in 2015 in Mill Valley, California, developing novel therapeutics with a small team and venture funding from NEA, Takeda Ventures, and other biotech investors.
Ownership category
akta.pro rank

OrphoMed industry classification

Industry
Product category
Pharmaceutical Drug Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals

Keywords

  • Novel therapeutics development
  • Small molecule drugs
  • Pharmaceutical research
  • Clinical-stage biopharma
  • Drug discovery

Where OrphoMed is headquartered

Location

Headquarters

HQ city
Mill Valley
HQ country
United States
HQ region
North America

Markets served

OrphoMed business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

OrphoMed product offering

Product offering

Core offering

OrphoMed is a San Francisco Bay Area pharmaceutical company founded in 2015 that develops novel therapeutics. The firm operates a small, focused R&D operation (1-10 employees) and has been funded by life-sciences venture investors to advance its pharmaceutical pipeline from medicinal chemistry through regulatory development.

Differentiator

Problem solved

Functional benefit

Companies that use OrphoMed

Customer profile

Ideal customer profiles1 record

OrphoMed technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

OrphoMed partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights3 records

OrphoMed competitors and assessment

Company assessment

Broad incumbents

  • Takeda Pharmaceutical: Large pharmaceutical strategic that led OrphoMed's Series A through Takeda Ventures, with a substantial GI specialty franchise (including the former Shire GI portfolio) making it both a potential acquirer and a directly relevant commercial comparator.
  • Salix Pharmaceuticals (Bausch Health): Established commercial-stage GI specialty pharma and a potential strategic acquirer of OrphoMed's assets; offers directly competing and complementary therapies in IBS-D and related GI conditions.

Direct peers

  • Ardelyx: Clinical-stage specialty pharmaceutical company developing novel therapeutics for GI and cardiorenal disorders, closely comparable to OrphoMed's small-molecule, GI-focused drug development model.
  • Ironwood Pharmaceuticals: GI-focused specialty pharmaceutical company developing therapeutics for IBS and other GI motility disorders, making it a directly comparable peer in target indication and therapeutic category.
  • RedHill Biopharma: Specialty pharma focused on GI and infectious diseases with a small-molecule pipeline, comparable to OrphoMed in size, stage, and therapeutic focus on GI disorders.
  • Synergy Pharmaceuticals: Specialty pharma that developed therapies for IBS-D and chronic GI conditions, providing a directly comparable business model, indication focus, and small-cap pharma profile (despite later restructuring).

Emerging players

  • Synthetic Biologics: Small-cap clinical-stage pharmaceutical company developing GI-focused therapeutics, comparable to OrphoMed in stage, size, and therapeutic category overlap.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key highlights4 records

Customer concentration

OrphoMed social profiles

Digital presence

OrphoMed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OrphoMed leadership team

Management profile

Number of profiles

OrphoMed funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OrphoMed M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OrphoMed

What does OrphoMed do?

OrphoMed is a San Francisco Bay Area pharmaceutical company founded in 2015 that develops novel therapeutics. The firm operates a small, focused R&D operation (1-10 employees) and has been funded by life-sciences venture investors to advance its pharmaceutical pipeline from medicinal chemistry through regulatory development.

When was OrphoMed founded?

OrphoMed was founded in 2015. It employs 1 to 10 people.

Where is OrphoMed based?

OrphoMed is headquartered in Mill Valley, United States, in the North America region.

Who are OrphoMed's main competitors?

Broad incumbents on record are Takeda Pharmaceutical and Salix Pharmaceuticals (Bausch Health). Direct peers are Ardelyx, Ironwood Pharmaceuticals, RedHill Biopharma and Synergy Pharmaceuticals. Synthetic Biologics is listed as an emerging player.

Does OrphoMed have an API?

No public API is recorded for OrphoMed.

What industry is OrphoMed in?

OrphoMed's product category is Pharmaceutical Drug Development. Its primary akta.pro industry code is HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogOrphoMed Resumes Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-DOrphoMed, Inc. announced the resumption of patient recruitment for its Phase 2 adaptive design study of ORP-101 for the treatment of irritable bowel syndrome with diarrhea (IBS-D). The screening process had been paused on March 27, 2020, due to the COVID-19 pandemic and will restart site-by-site as local authorities lift shelter-in-place directives. OrphoMed is collaborating with contract research organization PPD to ensure continued safety for patients and staff during this staggered enrollment phase.PR NewswireOrphoMed to Present at the 2019 BIO Investor ForumOrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, announced that Founder and Chief Scientific Officer Nikhilesh N. Singh will present at the BIO Investor Forum on October 22-23, 2019, in San Francisco. The presentation will take place at The Westin St. Francis hotel and will cover the company's pipeline, including ORP-101, a buprenorphine dimer in clinical development for IBS-D treatment. The company completed a $39 million Series A financing in May 2017 with backing from New Enterprise Associates, Takeda Ventures, Pappas Capital, and Relativity Healthcare.PR NewswireOrphoMed Announces Formation of Scientific Advisory BoardOrphoMed, a clinical-stage biopharmaceutical company based in San Francisco, announced the formation of a Scientific Advisory Board comprised of six gastrointestinal and drug development experts from leading medical institutions. The SAB will work with the company's leadership team to advance ORP-101, a drug candidate for diarrhea-predominant irritable bowel syndrome, into Phase 2 clinical development. The company completed a $39 million Series A financing in May 2017 with investors including New Enterprise Associates, Takeda Ventures, Pappas Capital, and Relativity Healthcare.PR NewswireFDA Grants Fast Track Designation for OrphoMed's ORP-101 for Treatment of IBS-DThe FDA granted Fast Track designation to OrphoMed's lead candidate ORP-101 for treating irritable bowel syndrome with diarrhea (IBS-D), a chronic condition affecting over 28 million individuals in the United States and Europe with limited treatment options. Fast Track designation enables early and frequent communications between the FDA and OrphoMed throughout the drug development process and makes the drug eligible for priority review of any future New Drug Application. The company aims to advance ORP-101 into Phase 2 clinical trials by the end of 2018.PR NewswireOrphoMed Appoints Gary M. Phillips, M.D. as President and Chief Executive OfficerOrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics for gastrointestinal disorders, announced the appointment of Gary M. Phillips, M.D. as President and Chief Executive Officer, effective immediately. Dr. Phillips, who joins from Mallinckrodt Pharmaceuticals where he served as Executive Vice President and Chief Strategy Officer, brings over two decades of pharmaceutical industry experience to the role. Founder Nikhilesh Singh, Ph.D., who led OrphoMed since its 2015 founding and guided it through a $39 million Series A financing and into clinical trials, transitions to the newly-created position of Chief Scientific Officer.PR NewswireOrphoMed to Present at the 2018 BIO CEO & Investor ConferenceOrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics for gastrointestinal disorders, announced that its President and CEO will present at the 20th Annual BIO CEO & Investor Conference in New York City on February 12, 2018. The presentation will cover the company's lead candidate ORP-101, a buprenorphine dimer in clinical development for the treatment of IBS-D, along with the company's broader pipeline of dimer conjugates. The announcement is a routine corporate presentation schedule disclosure with no material developments or financial milestones disclosed.PR NewswireOrphoMed lève 39 millions d'USD suite à un tour de table de série AOrphoMed, a clinical-stage pharmaceutical company based in San Francisco, raised $39 million in Series A funding led by New Enterprise Associates (NEA) and co-led by Takeda Ventures, with participation from Pappas Capital, Relativity Healthcare Partners, and Mario Family Fund. The capital will advance the clinical development of ORP-101, the company's lead candidate for treating irritable bowel syndrome with diarrhea (IBS-D), a peripherally-acting dimer molecule with exclusive rights owned by OrphoMed. The FDA has identified an urgent medical need for new IBS-D therapies, and expert opinion from Harvard Medical School highlights the drug's potential advantages over currently approved treatments.PR NewswireOrphoMed sichert sich eine Finanzierungsrunde der Serie A von 39 Millionen USDOrphoMed, Inc., a clinical-stage biopharma company based in San Francisco, announced the completion of a $39 million Series A financing round on May 29, 2017. The round was co-led by New Enterprise Associates (NEA) and Takeda Ventures, Inc., with participation from Pappas Ventures V, Relativity Healthcare Partners, and the Mario Family Fund. The capital will fund clinical development of ORP-101, a peripherally-acting opioid receptor dimer for treating irritable bowel syndrome with diarrhea (IBS-D), a condition affecting 10–20% of people in developed countries.PR NewswireOrphoMed consigue una ronda de financiación de serie A de 39 millones de dólaresOrphoMed, Inc., a clinical-stage biopharmaceutical company headquartered in San Francisco, announced on May 29, 2017 the completion of a $39 million Series A financing round to advance its lead drug candidate ORP-101 for treating diarrhea-predominant irritable bowel syndrome (IBS-D). The round was led by New Enterprise Associates (NEA) and co-led by Takeda Ventures, Inc., with participation from Pappas Capital, Relativity Healthcare Partners, and the Mario Family Fund. The funding will support the clinical development of ORP-101, a peripherally-acting opioid receptor dimer designed to address visceral hypersensitivity and gastrointestinal hypermotility without central nervous system penetration.PR NewswireOrphoMed Secures $39 Million Series A Financing RoundOrphoMed, a San Francisco-based clinical-stage biopharmaceutical company, announced the completion of a $39 million Series A financing round led by New Enterprise Associates (NEA) and co-led by Takeda Ventures, with participation from Pappas Capital, Relativity Healthcare Partners, and the Mario Family Fund. The capital will fund clinical development of ORP-101, a peripherally acting μ/κ dual opioid receptor dimer for treating irritable bowel syndrome with diarrhea (IBS-D). NEA partner Frank Torti and Pappas Capital Managing Partner Arthur Pappas will join OrphoMed's board alongside existing directors.